TD Asset Management Inc Has $36.07 Million Stock Holdings in Natera, Inc. $NTRA

TD Asset Management Inc boosted its stake in Natera, Inc. (NASDAQ:NTRA) by 21.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 157,466 shares of the medical research company’s stock after purchasing an additional 27,860 shares during the quarter. TD Asset Management Inc’s holdings in Natera were worth $36,074,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of NTRA. Integrated Wealth Concepts LLC grew its holdings in Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares during the period. NewEdge Advisors LLC grew its holdings in Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares during the period. Focus Partners Wealth grew its holdings in Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares during the period. Sivia Capital Partners LLC acquired a new stake in Natera in the second quarter worth $298,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Natera during the second quarter valued at about $558,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Price Performance

Shares of NASDAQ NTRA opened at $215.31 on Friday. The company has a 50-day moving average price of $204.19 and a 200-day moving average price of $216.06. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The stock has a market capitalization of $30.83 billion, a P/E ratio of -132.09 and a beta of 1.56.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 41,124 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the transaction, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at $24,035,465.29. This trade represents a 27.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Burkes Brophy sold 3,070 shares of the firm’s stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $193.74, for a total transaction of $594,781.80. Following the transaction, the chief financial officer directly owned 58,291 shares in the company, valued at $11,293,298.34. The trade was a 5.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 156,530 shares of company stock valued at $33,914,062 over the last ninety days. Company insiders own 5.05% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of analyst reports. William Blair initiated coverage on shares of Natera in a report on Tuesday, April 14th. They set an “outperform” rating for the company. Morgan Stanley reduced their price objective on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. The Goldman Sachs Group initiated coverage on shares of Natera in a report on Friday. They set a “neutral” rating and a $245.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Finally, Robert W. Baird set a $265.00 price objective on shares of Natera in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $256.12.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.